PDCD1 and lung carcinoma: Immune-checkpoint inhibitors (ICIs) towards programmed cell death protein-1 (PD-1)/ programmed death ligand-1 (PD-L1) have revolutionized the treatments of lung cancer and substantially elevated the survival of patients with lung cancer.